Skip to content
★ Sign in to follow
MBX Biosciences, Inc. logo

MBX Biosciences, Inc. Stock: price and insider trades · United States

US·Mcap US$2.7BHealth Care

No insider purchase over the last 90 days. The latest, by Hawryluk P. Kent, was filed 16 Mar 2026.

Insider Decl.
80
Thresholds
n/a
Buy Volume
€44M
14 ops. · all time
Sell Volume
€277,920
3 ops. · all time

Who traded when

BuySale
Hawryluk P. Kent3 buys
Orbimed Advisors LLC3 buys
Salomon Azoulay2 sales
Steven L. Hoerter1 buy1 sale
Carl L. Gordon1 buy
Ora H. Pescovitz1 buy

+1 other insider

Since the insiders bought

  • Filed 16 Mar 2026 · 246 days ago · €456k
    +83.3%
    Entry US$29.74 · Close 12 Nov 2026 US$54.51
  • Filed 20 Oct 2025 · 393 days ago · €226k
    +256.0%
    Entry US$15.31 · Close 12 Nov 2026 US$54.51
  • Filed 30 Sept 2025 · 413 days ago · €10.3M
    +215.9%
    Entry US$17.90 · Close at T+365 US$56.55

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Analyst consensus: bullish or bearish?

Analysts rate MBX Biosciences, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$95.70.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

as of FY 2025

FY ended December 2025 · cache

US$56.33
Analyst consensus
10 analysts
Strong buy
US$80.00Target US$95.70(+70%)US$150.00
Income statement
EBITDA-US$97.8M
Net income-US$87M0.0% margin
Valuation
PER (forward)-13.4x
P/Book6.9x
Beta0.18
Balance sheet & cash
Market capUS$2.7B
Total debtUS$596k
Free Cash Flow-US$81.9M
Debt / Equity1%
Profitability & ownership
ROE-33.2%
ROA-22.1%
% insiders2.9%
% institutions116.5%
Last declaration on 12 November 2026

T+90 is the date 90 days after the filing, the exit horizon used to measure each purchase.

Declarations80 total
  • ▼
    Chairman, President and CEOExecutives
    268,234 USD45SEC
    4,893 shares@ US$54.820.0098% mcap33.9% of flowCommon StockSEC:0001193125-26-457015:0
  • ●
    DirectorExecutives
    268,248 USD24Source
    4,893 shares@ US$54.82290.0098% mcap51.3% of flowCommonSEC144:0001959173-26-007930
  • ▼
    Chief Medical OfficerExecutives
    20,127 USD20SEC
    373 shares@ US$53.960.0008% mcap22.9% of flowCommon StockSEC:0001193125-26-449832:0
  • ●
    OfficerExecutives
    20,127 USD21Source
    373 shares@ US$53.95920.0008% mcap29.7% of flowCommonSEC144:0001959173-26-007744
  • ●
    Former OfficerExecutives
    255,737 USD24Source
    3,745 shares@ US$68.28760.0092% mcap9.3% of flowCommonSEC144:0001959173-26-006112
  • ▼
    Chief Medical OfficerExecutives
    24,335 USD14SEC
    370 shares@ US$65.770.0009% mcap27.1% of flowCommon StockSEC:0001193125-26-335373:0
  • ●
    OfficerExecutives
    24,336 USD14Source
    370 shares@ US$65.77290.0009% mcap27.1% of flowCommonSEC144:0001959173-26-005628
  • ●
    Officer, DirectorExecutives
    61,563 USD15Source
    936 shares@ US$65.77290.0023% mcap2.2% of flowCommonSEC144:0001959173-26-005629
  • ◆
    Chief Financial OfficerExecutives
    0SEC
    28,000 shares0Common StockSEC:0001193125-26-331642:0
  • ◆
    President and CEOExecutives
    0SEC
    71,000 shares0Common StockSEC:0001193125-26-331639:0
  • ●
    Former OfficerExecutives
    280,010 USD16Source
    9,167 shares@ US$30.54540.0095% mcap46.6% of flowCommonSEC144:0001959173-26-004511
  • ●
    Former OfficerExecutives
    321,273 USD16Source
    10,833 shares@ US$29.65690.011% mcap53.4% of flowCommonSEC144:0001959173-26-004487
  • ▲
    President & CEOExecutives
    525,663 USD26SEC
    18,500 shares@ US$28.414219.1% of flowCommon StockSEC:0001193125-26-107268:0
    Canonical exit: 11 Jun 2026 (T+90)
  • ◇
    President & CEOExecutives
    460,288 USD26SEC
    28,768 shares@ US$16.0016.3% of flowCommon StockSEC:0001193125-26-082562:0
  • ◆
    Chief Financial OfficerExecutives
    0SEC
    15,000 shares0Common StockSEC:0001193125-26-035584:0
  • ◆
    President & CEOExecutives
    0SEC
    35,250 shares0Common StockSEC:0001193125-26-035582:0
  • ◆
    Chief Medical OfficerExecutives
    0SEC
    15,000 shares0Common StockSEC:0001193125-26-035587:0
  • ◇
    President & CEOExecutives
    594,292 USD28SEC
    182,859 shares@ US$3.2521.5% of flowCommon StockSEC:0001193125-25-252404:0
  • ▲
    President & CEOExecutives
    272,790 USD40SEC
    20,000 shares@ US$13.63959.8% of flowCommon StockSEC:0001193125-25-245411:0
    Canonical exit: 18 Jan 2026 (T+90)
  • ▲
    DirectorExecutives
    264,984 USD31SEC
    20,000 shares@ US$13.2492100.0% of flowCommon StockSEC:0001193125-25-243653:0
    Canonical exit: 15 Jan 2026 (T+90)
  • ▲
    DirectorExecutives
    12M USD19SEC
    666,666 shares@ US$18.00100.0% of flowCommon StockSEC:0001231919-25-000267:0
    Canonical exit: 25 Dec 2025 (T+90)
  • ▲
    DirectorExecutives
    45,312 USD19SEC
    7,693 shares@ US$5.89100.0% of flowCommon StockSEC:0000950170-25-052685:0
    Canonical exit: 7 Jul 2025 (T+90)
  • ▲
    DirectorExecutives

    Same trade as the filing by Orbimed Advisors LLC, counted once

    290,969 USD30SEC
    29,540 shares@ US$9.852.2% of flowCommon StockSEC:0000947871-25-000200:1
    Canonical exit: 15 May 2025 (T+90)
  • ▲
    DirectorExecutives

    Same trade as the filing by Orbimed Advisors LLC, counted once

    531,919 USD32SEC
    49,070 shares@ US$10.844.0% of flowCommon StockSEC:0000947871-25-000200:2
    Canonical exit: 19 May 2025 (T+90)
  • ▲
    DirectorExecutives

    Same trade as the filing by Orbimed Advisors LLC, counted once

    1M USD33SEC
    94,100 shares@ US$10.847.7% of flowCommon StockSEC:0000947871-25-000200:3
    Canonical exit: 19 May 2025 (T+90)

25 of 80 declarations

About MBX Biosciences, Inc.

MBX Biosciences, Inc. (XNAS, Health Care, market capitalisation of 2,712,858,368 USD) has 62 filings, 36 of them in 2024, 10 in 2025 and 16 in 2026, covering trades from September 16, 2024 to November 10, 2026. Purchases weigh heavily: 14 purchases worth EUR 44,242,534, with a median of EUR 512,426, against 2 sales worth EUR 39,003, or 88% of market trades. The pack flags 10 cluster-buy filings.

On September 16, 2024, four filers bought for EUR 30,549,340, including Tiba Aynechi (Director) for EUR 10,782,120 and Frazier Life Sciences X, L.P., a 10% owner, for EUR 8,985,100. Patrick J. Heron (Director) bought EUR 10,289,150 on September 26, 2025. P. Kent Hawryluk (President & CEO) has 8 filings, 3 of them purchases; Orbimed Advisors LLC (Director) has 6, 4 of them purchases.

Read moreShow less

The two sales are Salomon Azoulay's (Chief Medical Officer): EUR 21,132 on August 4, 2026 and EUR 17,871 on November 4, 2026. Over twelve months: 16 filings, one purchase, 2 sales. For 14 purchases, the median 90-day result is 3.6%, with 64% positive: stored past results, not a forecast.

Written on 12 November 2026 from the filings and market data available that day. Live figures are in the blocks above.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations

The weekly insider digest, free

One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.